Tang Capital Management’s Nektar Therapeutics NKTR Stock Holding History

Tang Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-156,541	Closed	-$1.33M	–	121
2023 Q4	$1.33M	Sell	156,541 -106,099	-40%	-$804K	0.12%	101
2023 Q3	$2.35M	Buy	262,640 +253,333	+2,722%	+$2.44M	0.33%	66
2023 Q2	$80.3K	Hold	9,307	–	–	0.01%	99
2023 Q1	$98.1K	Sell	9,307 -1,639	-15%	-$49.6K	0.01%	101
2022 Q4	$371K	Sell	10,946 -17,723	-62%	-$858K	0.05%	79
2022 Q3	$1.38M	Hold	28,669	–	–	0.17%	79
2022 Q2	$1.63M	Hold	28,669	–	–	0.25%	54
2022 Q1	$2.32M	Buy	+28,669	New	+$4.24M	0.46%	44
2016 Q3	–	Sell	-17,333	Closed	-$3.7M	–	12
2016 Q2	$3.7M	Hold	17,333	–	–	1.65%	8
2016 Q1	$3.58M	Buy	+17,333	New	+$3.33M	1.63%	9
2013 Q3	–	Sell	-60,737	Closed	-$10.5M	–	18
2013 Q2	$10.5M	Buy	+60,737	New	+$9.32M	4.15%	8

Other funds holding NKTR

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Tang Capital Management's NKTR Position: Q1 2024 in Review

Tang Capital Management sold out of Nektar Therapeutics (NKTR) in Q1 2024, closing a stake of 156,541 shares — an estimated $1.33M sold.

Tang Capital Management first reported a position in NKTR in Q2 2013 and held it in 11 quarters. The position peaked at $10.5M in Q2 2013. 124 funds tracked by Wall St. Rank hold NKTR as of Q1 2024.

Tang Capital Management reported no remaining Nektar Therapeutics position as of Q1 2024 after selling out during the quarter.
Tang Capital Management sold 156,541 Nektar Therapeutics shares in Q1 2024, an estimated $1.33M.
Tang Capital Management first reported a position in Nektar Therapeutics in Q2 2013 and held it in 11 quarters.
Tang Capital Management's Nektar Therapeutics position peaked at $10.5M in Q2 2013.
124 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2024.

Based on Tang Capital Management's 13F filing for Q1 2024, filed 15 May 2024.